Staphylococcus aureus with reduced vancomycin susceptibility among clinical isolates in Erbil City

Aza Bahadeen Taha; Sabria M.Said Al-Salihi

doi:10.15218/zjms.2014.0010

Authors

Aza Bahadeen Taha College of Nursing, Hawler Medical University, Erbil, Iraq.
Sabria M.Said Al-Salihi College of Nursing, Hawler Medical University, Erbil, Iraq.

DOI:

https://doi.org/10.15218/zjms.2014.0010

Keywords:

Vancomycin creep, Staphylococcus aureus, MRSA, MIC creep, Resistance

Abstract

Background and objective: Staphylococcus aureus (S. aureus) is responsible for a wide range of diseases and increased number of the strains that acquired resistance to antibiotics. The emergence of Vancomycin resistance of S. aureus has been a significant impact on human health. The distribution of Vancomycin minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) in S. aureus isolates, and compared antibiotic susceptibility to non-glycopeptideantibiotics in different Vancomycin MIC value groupswere assessed in this study. Methods: S. aureuswere isolated by standard method and subjected to MIC tested by broth microdilution method for Vancomycin and eight non-glycopeptideantibiotics, alsoVancomycin MBCs were determined. Results: Approximately 56% of S. aureus with a 0.5 µg/ml Vancomycin MIC were accounted, whereas 1.77% of S. aureushadan 8 µg/ml Vancomycin MIC. In other hand, most S. aureus had 1 and 2 µg/ml Vancomycin MBC. Conclusion: About half of the S. aureus isolates had 0.5 µg/ml of Vancomycin MIC. Relationship between Vancomycin MIC and resistance to non-glycopeptideantibiotics were observed, with increased Vancomycin MIC, the resistance to others antibiotics also elevated, and vice versa.

Metrics

Metrics Loading ...

References

Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32(1):108-15.

Otto M. Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu Rev Microbiol 2010; 64:143-62.

Tsuji BT, Rybak MJ, Cheung CM, Amjad M, Kaatz GW. Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents. DiagnMicrobiol Infect Dis 2007; 58(1):41-7.

Palavecino E. Community-acquired methicillin-resistant Staphylococcus aureus infections.Clin Lab Med 2004; 24(2):403-18.

Kim HB, Lee YS, Kim BS, Cha JO, Kwon SU, Lee HJ, et al. Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 microg/ml in Korea. Microb Drug Resist 2006; 12(1):33-8.

Wootton M, MacGowan AP, Walsh TR. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 2006; 50(12):4195-7.

Monaco M, Sanchini A, Grundmann H, Pantosti A. Vancomycin-heteroresistant phenotype in invasive methicillin-resistant Staphylococcus aureus isolates belonging to spa type 041. Eur J ClinMicrobiol Infect Dis 2010; 29(7):771-7.

Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44(6):1549-55.

Boyle-Vavra S, Ereshefsky B, Wang CC, Daum RS. Successful multiresistant community-associated methicillin-resistant Staphylococcus aureus lineage from Taipei, Taiwan, that carries either the novel Staphylococcal chromosome cassette mec (SCCmec) type VT or SCCmec type IV. J ClinMicrobiol 2005; 43(9):4719-30.

Pillar CM, Draghi DC, Sheehan DJ, Sahm DF. Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs. Diagn Microbiol Infect Dis 2008; 60(2):221-4.

Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J ClinMicrobiol 2006; 44(11):3883-6.

Tacconelli E. Screening and isolation for infection control. J Hosp Infect2009; 73(4):371-7.

Alp E, Leblebicioglu H, Doganay M, Voss A. Infection control practice in countries with limited resources. Ann ClinMicrobiolAntimicrob 2011; 10:36.

Miyazaki M, Takata T, Yoshimura H, Matsunaga A, Ohta D, Ishikura H, et al. Vancomycin bactericidal activity as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureusbacteremia. Antimicrob Agents Chemother 2011; 55(4):1819-20.

Yamaguchi Y, Hanaki H, Yanagisawa C, Ikeda-Dantsuji Y, Hashimoto T, Yazaki H, et al. Characterization of beta-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR) in a patient with septicemia during long-term vancomycin administration. J Infect Chemother 2009; 15(5):274-8.

Appelbaum PC. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).Int J Antimicrob Agents 2007; 30(5):398-408.

Satola SW, Farley MM, Anderson KF, Patel JB. Comparison of detection methods for heteroresistantvancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J ClinMicrobiol 2011; 49(1):177-83.

Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52(3):285-92.

Takesue Y, Nakajima K, Takahashi Y, Ichiki K, Ishihara M, Wada Y, et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother 2011; 17(1):52-7.

Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int J Antimicrob Agents 2011; 37(3):219-24.

Baddour MM, Abuelkheir MM, Fatani AJ. Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia. Ann ClinMicrobiolAntimicrob 2006; 5:30.

Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis 2006; 6:156.

Edwards B, Milne K, Lawes T, Cook I, Robb A, Gould IM. Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J Clin Microbiol 2012; 50(2):318-25.

Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus(VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007; 60(4):788-94.

Voss A, Mouton JW, van Elzakker EP, Hendrix RG, Goessens W, Kluytmans JA, et al. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). Ann Clin Microbiol Antimicrob 2007; 6:9.

Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23(1):99-139.

Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clin Microbiol Rev 2002; 15(3):430-8.

Stefani S, Goglio A.Methicillin-resistant Staphylococcus aureus: related infections and antibiotic resistance.Int J Infect Dis 2010; 14 (Suppl 4):19-22.

Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 2002; 56:657-75.

Prakash V, Lewis JS II, Jorgensen JH. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 2008; 52(12):4528.

Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36:429-39.

Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureusbacteremia. Clin Infect Dis 2008; 46(2):193-200.

Dhawan B, Gadepalli R, Rao C, Kapil A, Sreenivas V. Decreased susceptibility to vancomycin in meticillin-resistant Staphylococcus aureus: A 5 year study in an Indian tertiary hospital. J Med Microbiol 2010; 59(Pt 3):375-6.

Aguado JM, San-Juan R, Lalueza A, Sanz F, Rodríguez-Otero J, Gómez-Gonzalez C, et al. High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia. Emerg Infect Dis 2011; 17(6):1099-102.

Ho PL, Lo PY, Chow KH, Lau EH, Lai EL, Cheng VC, et al. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect 2010; 60(2):140-5.

Campanile F, Borbone S, Perez M, Bongiorno D, Cafiso V, Bertuccio T, et al. Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates. Int J Antimicrob Agents 2010; 36(5):415-9.

Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): Implications for therapy. F1000 Med Rep 2012; 4:4.

Vaudaux P, Huggler E, Bernard L, Ferry T, Renzoni A, Lew DP. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to under detection of glycopeptide-intermediate isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54(9):3861-70.

Griffiths JM, O'Neill AJ. Loss of function of the gdpP protein leads to joint β-lactam/glycopeptide tolerance in Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56(1):579-81.

Harrison LS. Staphylococci. In: Mahon CR, Lehman DC, Manuselis G, editors. Textbook of diagnostic microbiology, 3rd ed. Philadelphia: Elsevier; 2007. P. 367-407.

Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 8th ed. Approved Standard M07-A8. Wayne, PA, USA: CLSI; 2009.

Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. Wayne, PA, USA: CLSI: 2009.

French GL. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. J Antimicrob Chemother 2006; 58(6):1107-17.

Honda H, Doern CD, Michael-Dunne W, Warren DK. The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia. BMC Infect Dis 2011; 11:335.

Sader HS, Fritsche TR, Jones RN. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother 2006; 50(7):2330-6.

National Committee for Clinical Laboratory Standards. Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Standard M26-A. Villanova, PA, USA: NCCLS; 1999.

Vaudaux P, Lew DP. Tolerance of staphylococci to bactericidal antibiotics. Injury 2006; 37 (Suppl 2):15-9.

Archer GL. Staphylococcus aureus: A well-armed pathogen. Clin Infect Dis 1998; 26(5):1179-81.

Tang YW, Stratton CW. Staphylococcus aureus: An old pathogen with new weapons.Clin Lab Med 2010; 30(1):179-208.

Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J ClinMicrobiol 2004; 42(6):2398-402.

Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51(7):2582-6.

Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36(4):1020-7.

Webster D, Rennie RP, Brosnikoff CL, Chui L, Brown C. Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Canada. Diagn Microbiol Infect Dis 2007; 57(2):177-81.

Saderi H, Owlia P, Shahrbanooie R. Vancomycin resistance among clinical isolates of Staphylococcus aureus. Arch Iranian Med 2005; 8(2):100-3.

Yeh YC, Yeh KM, Lin TY, Chiu SK, Yang YS, Wang YC, et al. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia. J Microbiol Immunol Infect 2012; 45(3):214-20.

Denny AE, Peterson LR, Gerding DN, Hall WH. Serious staphylococcal infections with strains tolerant to bactericidal antibiotics. Arch Intern Med 1979; 139(9):1026-31.

Fitzgerald JR, Sturdevant DE, Mackie SM, Gill SR, Musser JM. Evolutionary genomics of Staphylococcus aureus: insights into the origin of methicillin-resistant strains and the toxic shock syndrome epidemic. Proc Natl Acad Sci 2001; 98(15):8821-6.

Choi EY, Huh JW, Lim CM, Koh Y, Kim SH, Choi SH, et al. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med 2011;37:639-6347.